1
Eli Lilly and Company, Indianapolis, IN, USA, 2 Daiichi Sankyo, Inc., Parsippany, NJ, USA OBJECTIVES: To characterize ACS-PCI patients including the index hospitalization charges and length-of-stay (LOS) in a US health benefit plan. METHODS: The data source was Invision from i3, a division of UnitedHealth. ACS diagnoses were from ICD-9 codes 410.xx or 411.1. PCI procedure codes were 00. 66, 36.0X, 92973, 92975, 92978 −92982, 92984, 92995/6 , and G0290/1. The definition of ACS-PCI was PCI within 30 days of an ACS diagnosis. The diagnosis related group (DRG) codes (555, 556, 557, 558) and corresponding descriptions are from Version 23 and 24. Charges are in 2006 dollars. Continuous enrollment was required during the year 2006 and a minimum of 1 year before the index PCI. Patients with a history of transient ischemic attack or stroke were excluded. A clopidogrel claim was required within 60 days after hospitalization. RESULTS: Of the 6687 patients who had ACS-PCI and met the other inclusion criteria, 5174 (77.4%) were male, 5587 (83.6%) were under 65 years of age, and 1777 (26.6%) had a diabetes diagnosis. Drug-eluting stents (DES, n = 5541, 82.9%) were frequently used. The 3249 patients with DRG557, DES with a major cardiovascular diagnosis (CVDx), had a mean length of stay (LOS) of 2.9 days and mean charges of $54,271. The 2292 patients with DRG558, DES without major CVDx, had a mean LOS of 1.7 days and mean charges of $44,230. The corresponding cohorts receiving bare metal stents (BMS) with (DRG555, n = 602) and without (DRG556, n = 187) major CVDx had mean LOS of 2.9 and 1.8 days with mean hospital charges of $46,106 and $34,109 respectively. CONCLUSIONS: For ACS patients who underwent PCI, the mean charge was approximately $10,000 higher and the mean LOS was 1 day longer for the cohort with major CVDx, as per the DRG definition, compared to the cohort without major CVDx.
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MANAGEMENT OF ACUTE ISCHEMIC STROKE IN THE USA
Rouleau A 1 , Mouchet J 2 , Guilhaume C 1 , Milea D 1 , Maier W 3 1 Lundbeck SAS, Issy-les-Moulineaux, France, 2 MAPI Research Trust, Lyon, France, 3 MAPI-EPI, London, UK OBJECTIVES: Describe the management of ischemic stroke patients in acute phase and its impact on long-term stroke evolution in the USA. METHODS: Medline was searched from 1999 to date and ISPOR Digest was screened to identify stroke cohorts and registries containing data for the last ten years in the USA. A ranking process was implemented to identify and select the relevant references. RESULTS: A total of 461 references were retrieved. The selection process led to the identification of 78 publications (42 cohorts, 9 registries and 5 database studies) of which 41 focused on ischemic stroke only. Sixty-nine percent of the studies were hospital-based and 31% population-based. The studies aimed to characterise determinants that impact acute phase management and outcomes, in particular demographic and clinical factors. Hospital settings and associated care facilities were studied in order to improve disease management by identifying specific barriers to the administration of the only available thrombolytic treatment (recombinant tissue-type plasminogen activator, rt PA) in acute phase. Of these studies, many were not applicable to all ischemic stroke patients. Studies documenting the use of rt-PA showed that: less than 25% of patients arrived within 3 hours (i.e. time eligibility criteria for therapy) and 38.3% to 48.2% of them were excluded because of medical contraindications. Consequently, 10.9% to 14% of ischemic patients should have been given rt PA, but in natural settings, only 3.2% actually received it. In addition, long-term evolution of ischemic patients (mortality, stroke recurrence and cardiac events) was documented in several studies, but the evolution of disability after more than 3-months was not assessed. CONCLUSIONS: As shown above, general information about management of ischemic stroke in acute phase is lacking. New cohort or registry studies aiming to better describe patterns of ischemic stroke care that influence short and long-term clinical and associated economic outcomes need to be developed. (2006) fee-for-service, Medicare Part D and low-income subsidy (LIS) or non-LIS eligibility. Study outcomes included any drug use, adherence (percent days covered (PDC) ≥0.8), and discontinuation (≥30-day continuous gap). The study employed a quasi-experimental design using a pre-(prior to donut hole) and post-(during donut hole) periods comparing three patient groups (non-LIS: without coverage, generic only coverage, and brand / generic coverage during the gap) with a contemporaneous control group (LIS: no coverage gap). A difference-in-difference approach was used with multiple regressions controlling for demographic characteristics, Medicare entitlement status, area-level information, and clinical risk. RESULTS: The donut hole was associated with statistically significant decreases in any drug use and PDC adherence, along with an increase in the likelihood of a discontinuation for both lipid lowering and antihypertensive drugs. The magnitude of impact was largest among patients without donut-hole drug coverage: 1.1% to 4.1% drop in probability of drug use; 4.4% to 12.1% decrease in adherence; and 4.5% to 12.5% increase in discontinuations (p < 0.01 for all). Impact was smallest among patients with both generic/brand drug coverage relative to the LIS controls. The donut hole had no impact on probability of using symptomatic drugs (anti-ulcer agents, antidepressants, and pain-killers). CONCLUSIONS: The donut hole was associated with statistically significant but modest drops in the use of drugs for asymptomatic conditions, but had no impact on drugs for symptomatic conditions. Patients with no coverage during the donut hole experienced the largest impacts.
PCV121 THE IMPACT OF PART D ON PREVIOUSLY UNINSURED MEDICARE BENEFICIARIES WITH HYPERTENSION
Shoemaker JS University of Maryland Baltimore, Baltimore, MD, USA OBJECTIVES: To assess the effect of Medicare Part D enrollment on changes in antihypertensive drug utilization for a nationally-representative sample of Medicare beneficiaries without prior prescription coverage. Part D enrollees have characteristics associated with above average drug use. To date, no nationally-representative studies have evaluated the impact of Part D on drug utilization controlling for these selection effects. Panel data methods address these biases in studying treatment for a chronic condition for which drug therapy can promote long term benefits. METHODS: Longitudinal Medicare Current Beneficiary Survey (MCBS) data from the year before and after implementation of Part D. Unit of observation is the person-trimester, defined as the interval between subsequent MCBS survey dates. Primary sample of beneficiaries reporting a diagnosis of hypertension without drug coverage in 2005 and completed all 6 survey rounds in 2005 and 2006 (N = 3039 person trimesters). Secondary control sample of beneficiaries continuously enrolled in employer-sponsored insurance (ESI) as a sensitivity analysis (N = 5,608 person trimesters). Fixed effects and difference-in-difference (DID) multivariate methods compare changes in drug fills over six 4-month periods for beneficiaries who enrolled in Part D and those who did not. RESULTS: A total of 67% of the primary sample enrolled in Part D. Descriptive trend analysis shows a monotonic increase in mean antihypertensive fills by trimester ranging from 4.0 to 7.1 for Part D enrollees, compared to a range from 2.7 to 4.4 for non-enrollees. In adjusted DID comparisons, Part D enrollees experienced 1.79 additional antihypertensive fills per trimester relative to non-enrollees (p < 0.05). Fixed effects methods suggest that Part D enrollees filled an additional 1.08 prescriptions per trimester (p < 0.05). Sensitivity analysis show comparable results. CONCLU-SIONS: Enrollment in Part D increased drug utilization for a class of drugs known to be effective in treating a highly prevalent, costly, and asymptomatic condition such as hypertension.
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IS PRESCRIBING JUSTIFIED BY THE EVIDENCE?-COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS FOR TREATING HYPERTENSIVE OUTPATIENTS IN SOUTHERN TAIWAN
Chang WY 1 , Chen LC 1 , Hung SH 1 , Chan HE 2 , Wu JS 2 1 Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Bureau of National Health Insurance, Kaohsiung, Taiwan OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have substantially contributed to the escalating antihypertensive drug cost in Taiwan. Increasing literature has proposed potential benefits of combing ACEIs/ARBs in controlling blood pressure, but there is still a lack of evidence to support the rationale of ACEIs/ARBs combination in treating hypertension. This study aims to explore the current utilization and prescribing patterns of ACEIs/ARBs combination in Taiwan. METHODS: A cross-sectional study was conducted from 2006 to 2008, using a regional reimbursement claim database from the KaoPing Division of National Health Insurance. Individual data of hypertensive outpatients treated with ACEIs or ARBs for more than 28 days per year in Southern Taiwan were extracted. Demographic and prescribing data were collected, and then descriptive analyses were used to evaluate patients' characteristics and prescribing patterns of ACEIs, ARBs and their combination. Wald chi-square tests and Student's t-test were conducted to examine the prescribing associated variables and differences between health care facilities. RESULTS: During the 3-year study period, 4,482,826 prescriptions were assessed, including 44.69% (n = 2,003,278) ACEIs and 55.31% (n = 2,479,548) ARBs prescriptions. Of all, 1.22% (n = 54,526) prescriptions have either doubled or combined more than one ACEI. Likewise, 2.29% (n = 102,486) have doubled or combined ARBs. Furthermore, 0.61% (n = 27,381) prescriptions combined both ACEIs and ARBs. The majority of these combinations were prescribed in medical centers in continuous prescriptions for long-term refills, and the amount of combined prescriptions increased annually. The major co-morbidity of ACEIs/ARBs combinations is diabetes mellitus (n = 9871, 36.05%), and chronic renal disease (n = 5055, 18.46%) and congestive heart failure (n = 886, 3.24%). CONCLUSIONS: We found a small proportion of ACEIs/ARBs combination, yet the combined prescriptions are increasing and used chronically in patients with specific co-morbidities. Further studies are needed to explore the effectiveness and rationality of this combination.
PCV123 DRUG UTILIZATION REVIEW OF DUAL ANTIPLATELET THERAPY AMONG TAIWANESE OLDER ADULTS
Yu IW 1 , Wu MY 2 , Chien CR 1 , Lin CH 1 , Lin WL 1 , Lin HW 2 1 China Medical University Hospital, Taichung, Taiwan, 2 China Medical University, Taichung, Taiwan OBJECTIVES: Upon the coverage limitations proposed by Taiwan National Health Insurance (NHI), the dual therapy with clopidogrel and aspirin would be reimbursed up to 9 months for specific indications since 2004. Although evidence showed its risks outweighed the benefits comparing to use aspirin alone, it is a lack of study examining population use of dual therapy. A secondary data analysis was performed to examine the use patterns of dual antiplatelet therapy (DAT), specifically among older adults in Taiwan. METHODS: A population-based longitudinal assessment was conducted using the 2003-2007 NHI databases. Those beneficiaries in 60 years old of age and greater during the study period were evaluated. All relevant data, including visits toward physician clinics, outpatient departments, use of medications, and pertinent coverage cost in the datasets of ambulatory care were retrieved and analyzed. Descriptive analysis was performed to describe and compare the utilization of DAT for less or greater than 3 months (shorter vs. longer treatment). RESULTS: Of half million beneficiaries being evaluated, 1099 patients were prescribed DAT. Of which, 71% were older adults (age = 71 ± 7.8 years old). There was a sharply increasing utilization of DAT in 2007 for a total of 785 older patients. 85% were prescribed with approval indications (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. 29.8% possessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which might attribute to DAT. The duration of DAT was up to 13 months. The total drug expenses were 66% and 85% among shorter and longer treatment patients, respectively. The cost of DAT accounted for up to 51% of total drug expense. CONCLU-SIONS: There were sharply increasing utilization of DAT among Taiwanese older adults since 2007. Further studies are needed to explore the contributing factors of DAT and its effectiveness and safety outcomes.
PCV124 ANTIHYPERTENSIVE PHARMACOTHERAPY-PHYSICIAN PERSPECTIVES AND PRESCRIBING PATTERNS IN THREE SOUTH INDIAN HOSPITALS
Sreedharan N 1 , Rao Padma G M 1 , Rau N R 1 , Shankar P R 2 1 Manipal University, Manipal, Karnataka, India, 2 KIST Medical College, Lalitpur, Kathmandu, Nepal OBJECTIVES: The prevalence of hypertension is increasing in epidemic proportions in the Indian subcontinent. Despite the well known benefits of aggressive blood pressure control in hypertensive patients, data from the subcontinent indicate that the control of hypertension remains remarkably poor. Our previous study demonstrated that calcium channel blockers (CCBs) were the most prescribed agents for uncomplicated hypertension in three South Indian Hospitals. The objective of this study was to assess the physician's perspectives with regard to antihypertensive pharmacotherapy and to determine whether they are in accordance to national and/or international hypertension guidelines. METHODS: A questionnaire was developed containing questions on familiarity with guidelines, diagnosis of clinical hypertension, and evaluation of patients with hypertension with or without co-morbidities, treatment of hypertension including choice of drugs, and drug regimens or specific drug combinations. The questionnaire was administered to interns and physicians of Medicine Department of three teaching-hospitals in South India. RESULTS: Among a total of 57 physicians who received the survey 58.1% expressed familiarity with the JNC-VII guidelines whereas 12.8% were familiar with the Indian Hypertension Guidelines-II. Although majority of the physicians were aware of the guidelines about 37% of them indicated that they would prefer CCBs as the first drug for treating uncomplicated hypertension. When asked about monotherapy versus combination therapy a majority (91.2%) of the physicians chose a two-drug combination over monotherapy. CCB with ACEinhibitors was the most favored choice followed by combinations of CCBs with beta-blockers and diuretics. CONCLUSIONS: The physician's preference of CCBs and combination therapy over other antihypertensives and monotherapy may be attributed to the better treatment outcomes they experienced and is consistent with emerging trends observed in recent studies such the ACCOMPLISH and ASCOT trials that underscore the benefits of using combination therapy with CCBs as initial therapy for hypertension.
PCV125 UTILIZATION PATTERNS FOR ANTIARRHYTHMIC DRUGS IN BIG 5 EU MARKETS: TEMPORAL ANALYSIS FROM 2005 TO 2009
Buono JL 1 , Bash LD 2 , Phatak H 2 1 St. John's University, College of Pharmacy and Allied Health Professions, Queens, NY, USA, 2 Merck & Co., Inc., Whitehouse Station, NJ, USA OBJECTIVES: This study evaluates changes in utilization patterns of class I (flecainide and propafenone) and class III (amiodarone) antiarrhythmics in France, Italy, Spain, Germany, and the UK from 2005 to 2009. These drugs are used for treatment of supraventricular and ventricular arrhythmias of which atrial fibrillation is the most common among the adult population. METHODS: Utilization trends were examined using IMS Market Trend Analysis, a database of global sales from all corporations with pharmaceutical products sold into a pharmacy or hospital as well as prescription information from office-based physicians. Utilization of antiarrhythmic drugs was assessed using patient days of therapy (PDoT). Descriptive analyses were conducted for specific drug classes as well as individual agents, including flecainide, propafenone, and amiodarone. RESULTS: Overall, PDoT was highest for amiodarone, the main representative class III agent, with an average of 229 million PDoT over the five year period across all markets. During this time, PDoT for amiodarone increased by 9.5% in Italy (50.9 to 55.7 million), 13.8% in Germany (32.9 to 37.5 million), and 0.5% in France (85.8 to 86.3 million) and decreased by 20.6% in the UK (32.8 to 26.0 million) and 2.5% in Spain (27.2 to 26.5 million). This resulted in greater class III drug use in all markets except Italy, where class I agents were preferred over class III agents consistently from 2005 to 2009. Among all antiarrhythmics, flecainide showed a consistent overall increase in PDoT over the study period, with a 22.4% increase from 110 to 135 million PDoT and a resulting increase in market share from 24% to 29.4% from 2005 to 2009. CONCLUSIONS: Amiodarone was the dominant antiarrhythmic in all markets. However, increases in flecainide use in 4 out of 5 European markets suggest a possible change in rhythm control strategy for the treatment and/ or management of arrhythmias.
